FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2042278655> ?p ?o ?g. }

• W2042278655 abstract "Abstract Background Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients. Methods Patients were administered oral celecoxib (400 mg/day) in combination with intravenous carboplatin (AUC5, q28). A Simon's two-stage design was employed. Results 45 patients were enrolled: 23 (51.1%) presented platinum-resistance, and 27 (60%) had received at least 3 prior regimens for recurrence. The response rate was 28.9% with 3 complete and 10 partial responses (median duration of response = 6 months). Only one (0.4%) G4 non-febrile neutropenia was observed; G3 neutropenia, anemia, or thrombocytopenia, were observed in 2.5%, 1.7%, and 1.7% of the cycles, respectively. G3-4 vomiting was reported in only 1.7%, and 0.4% of the cycles were associated with G3 dyspepsia or diarrhea or constipation. Only one patient experienced G3 hypertension associated to G2 hypersensitivity reaction. No differences in baseline versus post-treatment Quality of Life scores were observed. Median progression free survival and overall survival were 5 and 13 months, respectively. Conclusions Celecoxib combined with carboplatin showed promising activity and it is well tolerated in heavily-treated recurrent ovarian cancer patients. Trial registration number NCT01124435 (ClinicalTrials.gov Identifier) and 935/03 (study ID numbers)." @default.
• W2042278655 created "2016-06-24" @default.
• W2042278655 creator A5008677864 @default.
• W2042278655 creator A5018900204 @default.
• W2042278655 creator A5029193050 @default.
• W2042278655 creator A5030229940 @default.
• W2042278655 creator A5030733912 @default.
• W2042278655 creator A5042268927 @default.
• W2042278655 date "2011-05-31" @default.
• W2042278655 modified "2023-10-02" @default.
• W2042278655 title "Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients" @default.
• W2042278655 cites W169826043 @default.
• W2042278655 cites W1977047026 @default.
• W2042278655 cites W1982248155 @default.
• W2042278655 cites W2008778808 @default.
• W2042278655 cites W2020713814 @default.
• W2042278655 cites W2032615620 @default.
• W2042278655 cites W2038033170 @default.
• W2042278655 cites W2044421413 @default.
• W2042278655 cites W2051398284 @default.
• W2042278655 cites W2060125529 @default.
• W2042278655 cites W2071975250 @default.
• W2042278655 cites W2076197602 @default.
• W2042278655 cites W2104071578 @default.
• W2042278655 cites W2104998982 @default.
• W2042278655 cites W2105130747 @default.
• W2042278655 cites W2109322259 @default.
• W2042278655 cites W2109713333 @default.
• W2042278655 cites W2117011972 @default.
• W2042278655 cites W2118268216 @default.
• W2042278655 cites W2133506440 @default.
• W2042278655 cites W2136383268 @default.
• W2042278655 cites W2136753100 @default.
• W2042278655 cites W2139248078 @default.
• W2042278655 cites W2145818888 @default.
• W2042278655 cites W2151050516 @default.
• W2042278655 cites W2158968701 @default.
• W2042278655 cites W2163756514 @default.
• W2042278655 cites W2167571044 @default.
• W2042278655 cites W2267902670 @default.
• W2042278655 cites W2336169581 @default.
• W2042278655 cites W4240700329 @default.
• W2042278655 cites W4293241248 @default.
• W2042278655 doi "https://doi.org/10.1186/1471-2407-11-214" @default.
• W2042278655 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/3123659" @default.
• W2042278655 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/21627839" @default.
• W2042278655 hasPublicationYear "2011" @default.
• W2042278655 type Work @default.
• W2042278655 sameAs 2042278655 @default.
• W2042278655 citedByCount "42" @default.
• W2042278655 countsByYear W20422786552012 @default.
• W2042278655 countsByYear W20422786552013 @default.
• W2042278655 countsByYear W20422786552014 @default.
• W2042278655 countsByYear W20422786552015 @default.
• W2042278655 countsByYear W20422786552016 @default.
• W2042278655 countsByYear W20422786552017 @default.
• W2042278655 countsByYear W20422786552018 @default.
• W2042278655 countsByYear W20422786552019 @default.
• W2042278655 countsByYear W20422786552020 @default.
• W2042278655 countsByYear W20422786552021 @default.
• W2042278655 countsByYear W20422786552022 @default.
• W2042278655 countsByYear W20422786552023 @default.
• W2042278655 crossrefType "journal-article" @default.
• W2042278655 hasAuthorship W2042278655A5008677864 @default.
• W2042278655 hasAuthorship W2042278655A5018900204 @default.
• W2042278655 hasAuthorship W2042278655A5029193050 @default.
• W2042278655 hasAuthorship W2042278655A5030229940 @default.
• W2042278655 hasAuthorship W2042278655A5030733912 @default.
• W2042278655 hasAuthorship W2042278655A5042268927 @default.
• W2042278655 hasBestOaLocation W20422786551 @default.
• W2042278655 hasConcept C121608353 @default.
• W2042278655 hasConcept C126322002 @default.
• W2042278655 hasConcept C141071460 @default.
• W2042278655 hasConcept C143998085 @default.
• W2042278655 hasConcept C2776467144 @default.
• W2042278655 hasConcept C2776694085 @default.
• W2042278655 hasConcept C2777063308 @default.
• W2042278655 hasConcept C2778239845 @default.
• W2042278655 hasConcept C2778850193 @default.
• W2042278655 hasConcept C2780427987 @default.
• W2042278655 hasConcept C2780580376 @default.
• W2042278655 hasConcept C2781451048 @default.
• W2042278655 hasConcept C71924100 @default.
• W2042278655 hasConcept C90924648 @default.
• W2042278655 hasConceptScore W2042278655C121608353 @default.
• W2042278655 hasConceptScore W2042278655C126322002 @default.
• W2042278655 hasConceptScore W2042278655C141071460 @default.
• W2042278655 hasConceptScore W2042278655C143998085 @default.
• W2042278655 hasConceptScore W2042278655C2776467144 @default.
• W2042278655 hasConceptScore W2042278655C2776694085 @default.
• W2042278655 hasConceptScore W2042278655C2777063308 @default.
• W2042278655 hasConceptScore W2042278655C2778239845 @default.
• W2042278655 hasConceptScore W2042278655C2778850193 @default.
• W2042278655 hasConceptScore W2042278655C2780427987 @default.
• W2042278655 hasConceptScore W2042278655C2780580376 @default.
• W2042278655 hasConceptScore W2042278655C2781451048 @default.
• W2042278655 hasConceptScore W2042278655C71924100 @default.
• W2042278655 hasConceptScore W2042278655C90924648 @default.
• W2042278655 hasIssue "1" @default.
• W2042278655 hasLocation W20422786551 @default.

• next